Prostate cancer chemoprevention: strategies for designing efficient clinical trials

Urology

Volumn 57, Issue 4 SUPPL. 1, 2001, Pages 224-229

  Lieberman, Ronald ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; HUMAN; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PROSTATE TUMOR; REPRODUCIBILITY; TUMOR RECURRENCE;

ANTICARCINOGENIC AGENTS; CLINICAL TRIALS; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; TUMOR MARKERS, BIOLOGICAL;

EID: 0035318508     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0090-4295(00)00981-x     Document Type: Article

References (24)

1. Feigal P, Blumenstein B, Thompson I, et al: Design of the prostate cancer prevention trial (PCPT). Control Clin Trials 16: 150-163, 1995.
2. Defeating Prostate Cancer: Crucial Direction for Research. Report of the Prostate Cancer Progress Review Group, August 1998;
3. 1998. Bethesda, MD: National Cancer Institute. Available at: http://www.nci.nih.gov.
4. Greenwald P, and Lieberman R: Chemoprevention trials for prostate cancer, in Chung L, Isaacs W, and Simons J (Eds): Prostate Cancer in the 21st Century. Totowa, NJ, Humana Press Inc., 2001, pp 499-518.
5. Norrish AE, Jackson RT, and McRae CV: Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer 77: 511-515, 1998.
6. Nelson JE, and Harris RE: Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs). Results of a case-control study. Oncol Rep 7: 169-176, 2000.
7. Clark LC, Combs GF, Turnbull BW, et al: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized control trial. JAMA 276: 1957-1963, 1996.
8. Heinonen OP, Albanes D, Virtano J, et al: Prostate cancer and supplementation with alpha-tocopherol and beta-carotene. Incidence and mortality in a controlled trial. J Natl Cancer Inst 90: 440-446, 1998.
9. Kelloff GJ, Lieberman R, Steele VE, et al: Chemoprevention of prostate cancer: concepts and strategies. Eur Urol; 35: 342-350, 1999.
10. Kelloff G, Lieberman R, Brawer BK, et al: Strategies for chemoprevention of prostate cancer. Prostate Cancer Prostate Dis 2: 27-33, 1999.
11. Lieberman R, Crowell JA, Hawk ET, et al: Development of new cancer chemoprevention agents: the role of pharmacokinetic-pharmadynamic and intermediate endpoint biomarker monitoring. Clin Chem 44(2): 420-427, 1998.
12. Sakr WA, Haas GP, Cassin BJ, et al: The frequency of carcinoma and intraepithelial neoplasia of prostate in young male patients. J Urol 150: 378-385, 1993.
13. Bartels PH: Computer-generated diagnosis and image analysis: an overview. Cancer 69: 1636-1638, 1992.
14. Strausberg RL, Dahl CA, and Klausner RD. New opportunities for uncovering the molecular basis of cancer. Nat Genet 15: 415-416, 1997.
15. 3) spatial resolution. Radiology 198: 795-805, 1996.
16. Mairinger T, Mickey G, and Gschmendtner A: Nuclear chromatin texture analysis of non-malignant tissue can detect adjacent prostate adenocarcinoma. Prostate 41: 12-19, 1999.
17. Bartels PA, Montironi R, Hamilton PN, et al: Nuclear chromatin texture in prostate lesions. II. Pin and malignancy associated changes. Anal Quant Cyt Histol 20: 397-406, 1998.
18. Smith JR, Freije D, Carpten JD, et al: Major susceptibil-ity locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274: 1371-1374, 1996.
19. Bostwick DG: Target populations and strategies, for chemoprevention trials of prostate cancer. J Cell Biochem Suppl 19: 191-196, 1994.
20. Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281: 1591-1617, 1999.
21. Keetch DW, Catalona WJ, and Smith DS: Serial prostate biopsies in men with persistently elevated serum prostate-specific antigen values. J Urol 151: 1571- 1574, 1994.
22. Partin AW, Piantadosi S, Sanda MG, et al: Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology 45: 831-838, 1995.
23. Kattan MW, Wheeler TM, and Scardino PT: Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 17: 1499-1507, 1999.
24. Blute ML, Bergstrahl EJ, Iocca A, et al: Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 165: 119-125, 2001.